Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer
1
Department of Oncology, University of Calgary, Calgary, AB, Canada
2
Tom Baker Cancer Centre, Calgary, AB, Canada
3
Department of Internal Medicine, Max Rady College of Medicine, Winnipeg, MB, Canada
4
Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s2), 106-114; https://doi.org/10.3747/co.27.5549
Submission received: 7 January 2020
/
Revised: 3 February 2020
/
Accepted: 10 March 2020
/
Published: 1 April 2020
Abstract
Immune checkpoint inhibitor–based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell–mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.
Keywords:
immune checkpoints; PD-1; PD-L1; ctla-4; biomarkers
Share and Cite
MDPI and ACS Style
Meyers, D.E.; Banerji, S. Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Curr. Oncol. 2020, 27, 106-114. https://doi.org/10.3747/co.27.5549
AMA Style
Meyers DE, Banerji S. Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology. 2020; 27(s2):106-114. https://doi.org/10.3747/co.27.5549
Chicago/Turabian StyleMeyers, D.E., and S. Banerji. 2020. "Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer" Current Oncology 27, no. s2: 106-114. https://doi.org/10.3747/co.27.5549
